Genetic association between plasminogen activator inhibitor‐1 rs1799889 polymorphism and venous thromboembolism: Evidence from a comprehensive meta‐analysis

BACKGROUND: Association between plasminogen activator inhibitor‐1 (PAI‐1) rs1799889 polymorphism and venous thromboembolism (VTE) were explored by many previous studies, yet the findings of these studies were conflicting. HYPOTHESIS: PAI‐1 rs1799889 polymorphism may serve as a genetic marker of VTE. We aimed to better clarify the relationship between PAI‐1 rs1799889 polymorphism and VTE in a larger combined population by performing a meta‐analysis. METHODS: Literatures were searched in Pubmed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI). We used Review Manager to combine the results of individual studies. RESULTS: Forty‐eight studies involving 14 806 participants were eligible for inclusion. Combined results revealed that PAI‐1 rs1799889 polymorphism was significantly associated with VTE in Caucasians (dominant comparison: odds ratio [OR] 1.20, 95% confidence interval [CI] 1.09‐1.32; recessive comparison: OR 0.84, 95% CI 0.76‐0.94; allele comparison: OR 1.08, 95% CI 1.02‐1.15) and East Asians (dominant comparison: OR 1.60, 95% CI 1.17‐2.19; allele comparison: OR 1.53, 95% CI 1.21‐1.93). Further analyses obtained similar significant associations in these with deep vein thrombosis (DVT) and these with Factor V Leiden mutation. CONCLUSIONS: Our findings supported that PAI‐1 rs1799889 polymorphism may serve as one of the predisposing factors of VTE in both Caucasians and East Asians, especially in these with DVT and these with Factor V Leiden mutation.